According to Future Market Insights, the Respiratory Distress Syndrome Management Market is projected to rise at a steady growth valued at US$ 115.4 billion with a 4.41% CAGR until 2033, being valued at US$ 177.7 billion.

The need for RDS treatment is generated by an increase in hospital admissions and admissions to the critical care unit, which propels the market's expansion. 18.4% of patients with respiratory distress syndrome required re-hospitalization, according to a study titled "Respiratory distress syndrome readmissions: A countrywide cross-sectional analysis of epidemiology and costs of care" that was published in the PLOS One Journal in January 2022.

Additionally, according to data from the Australian Institute of Health and Welfare published in May 2022, there were 11.8 million hospital admissions in 2020–21, an increase of 6.3% from 2019–20. Out of 11.8 million admissions, it was also reported that 7.0% of hospitalizations involved an ICU stay, 3.8% of hospitalizations involved respiratory disease, and 10.3% of hospitalizations had a separation mode indicating the patient passed away in the hospital. The market segment is anticipated to grow as a result of the rising number of admissions into emergency critical care, which creates a need for RDS treatment.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16979

The market is expanding due to the increasing need for diagnoses. As many patients require several diagnoses for the treatment to be finished promptly, the diagnosis sector is predicted to dominate the market. As a result, the market has a huge opportunity. The development of the global respiratory distress syndrome treatment market during the forecast period may be restrained by a lack of qualified specialists who are ignorant of the available treatment options for this illness.

Key Takeaways from the Market Study:

• It is noted that the industry sponsors will be leading the market with an expected share of about 54.7% in the year 2023, within the global market.
• The global Respiratory Distress Syndrome Management Market grew at a CAGR of 4.24% from 2018 to 2022
• 4% of patients with respiratory distress syndrome required re-hospitalization.
• Out of 11.8 million admissions, it was also reported that 7.0% of hospitalizations involved an ICU stay, 3.8% of hospitalizations involved respiratory disease, and 10.3% of hospitalizations had a separation mode indicating the patient passed away in the hospital.

Competitive Landscape:

Some of the prominent players in the global market for RDS treatment are:

• JW Pharmaceutical
• Windtree Therapeutics, Inc.
• ONY Biotech Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc.
• Pfizer Inc.
• Gilead Sciences, Inc.
• Hoffmann-La Roche Ltd
• Fresenius Kabi AG

Some of the important developments of the key players in the market are:

• In May 2021, Medtronic announced the launch of the SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio.
• In July 2020, F. Hoffman-La Roche Ltd announced the launch of the SARS-CoV-2 rapid antibody test. The test was launched in partnership with SD Biosenseor, Inc. This has helped the company to increase its product portfolio.

Key Segments Profiled in the Respiratory Distress Syndrome Management Market Report

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Drug Class:

• Vasoconstrictors
• Bronchodilators
• Steroids and Antibiotics

Route of administration:

• Oral
• Parenteral
• Nasal

End User:

• Hospital pharmacy
• Online pharmacy
• Retail pharmacy